Summary of the characteristics of patients treated with topical ciclosporin (Ikervis) in Nottingham, UK
| Parameters | Total n=463 |
| n (%) | |
| Age, years | |
| 0–18 | 34 (7.3) |
| >18 to 30 | 44 (9.5) |
| >31 to 50 | 98 (21.2) |
| >51 to 70 | 152 (32.8) |
| >70 | 135 (29.2) |
| Gender | |
| Female | 273 (59.0) |
| Male | 190 (41.0) |
| Diagnosis | |
| Dry eye diseases | 322 (69.5) |
| AED | 53 (11.4) |
| OMMP | 28 (6.0) |
| Post-corneal graft | 14 (3.0) |
| SJS | 10 (2.2) |
| Others* | 36 (7.8) |
| CDVA, logMAR | |
| Baseline | 0.24±0.45 |
| Final | 0.23±0.47 |
| Clinical outcome† | |
| Resolved | 119 (25.7) |
| Stable | 224 (48.4) |
| Active | 44 (9.5) |
| Intolerant to Ikervis | 76 (16.4) |
| Treatment frequency | |
| Once a day | 286 (61.8) |
| Twice a day | 173 (37.4) |
| >Twice a day | 4 (0.9) |
| Follow-up duration, months | 14.6±9.2 |
*Included cases of inflammatory keratitis (n=9), non-specific chronic conjunctivitis (n=7), scleritis/episcleritis (n=4), limbal stem cell deficiency (n=3), neurotrophic keratopathy (n=2), pseudopterygium (n=2), peripheral ulcerative keratitis (n=2), superior limbic keratoconjunctivitis (n=2), uveitis (n=2), epithelial ingrowth (n=1), conjunctival granuloma (n=1) and giant papillary conjunctivitis (n=1).
†Clinical outcome is defined as: (1) resolved: resolution of disease without further need of Ikervis; (2) stable: stable disease with ongoing Ikervis; (3) active: active disease requiring additional treatment such as topical steroids and (4) intolerant: Ikervis discontinued due to intolerable side effects.
AED, allergic eye disease (which included vernal keratoconjunctivitis and atopic keratoconjunctivitis; CDVA, corrected distance visual acuity; OMMP, ocular mucous membrane pemphigoid; SJS, Steven-Johnson syndrome.